Literature DB >> 18951408

PIK3CA somatic mutations in breast cancer: Mechanistic insights from Langevin dynamics simulations.

Parminder K Mankoo1, Saraswati Sukumar, Rachel Karchin.   

Abstract

Somatic mutations in PIK3CA (phosphatidylinositol-3 kinase, catalytic subunit, alpha isoform) are reported in breast and other human cancers to concentrate at hotspots within its kinase and helical domains. Most of these mutations cause kinase gain of function in vitro and are associated with oncogenicity in vivo. However, little is known about the mechanisms driving tumor development. We have performed computational structural studies on a homology model of wildtype PIK3CA plus recurrent H1047R, H1047L, and P539R mutations, located in the kinase and helical domains, respectively. The time evolution of the structures show that H1047R/L mutants exhibit a larger area of the catalytic cleft between the kinase N- and C-lobes compared with the wildtype that could facilitate the entrance of substrates. This larger area might yield enhanced substrate-to-product turnover associated with oncogenicity. In addition, the H1047R/L mutants display increased kinase activation loop mobility, compared with the wildtype. The P539R mutant forms more hydrogen bonds and salt-bridge interactions than the wildtype, properties that are associated with enhanced thermostability. Mutant-specific differences in the catalytic cleft and activation loop behavior suggest that structure-based mutant-specific inhibitors can be designed for PIK3CA-positive breast cancers.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18951408      PMCID: PMC3094910          DOI: 10.1002/prot.22265

Source DB:  PubMed          Journal:  Proteins        ISSN: 0887-3585


  58 in total

1.  Identifying native-like protein structures using physics-based potentials.

Authors:  Brian N Dominy; Charles L Brooks
Journal:  J Comput Chem       Date:  2002-01-15       Impact factor: 3.376

2.  Insights into protein-protein binding by binding free energy calculation and free energy decomposition for the Ras-Raf and Ras-RalGDS complexes.

Authors:  Holger Gohlke; Christina Kiel; David A Case
Journal:  J Mol Biol       Date:  2003-07-18       Impact factor: 5.469

Review 3.  Structure and function of phosphoinositide 3-kinases.

Authors:  M P Wymann; L Pirola
Journal:  Biochim Biophys Acta       Date:  1998-12-08

4.  ANOLEA: a www server to assess protein structures.

Authors:  F Melo; D Devos; E Depiereux; E Feytmans
Journal:  Proc Int Conf Intell Syst Mol Biol       Date:  1997

Review 5.  Targeting phosphoinositide 3-kinase: moving towards therapy.

Authors:  Romina Marone; Vladimir Cmiljanovic; Bernd Giese; Matthias P Wymann
Journal:  Biochim Biophys Acta       Date:  2007-10-12

6.  Mutational hotspot in exon 20 of PIK3CA in breast cancer among Singapore Chinese.

Authors:  Xiaohui Liang; Quek Choon Lau; Manuel Salto-Tellez; Thomas Choudary Putti; Marie Loh; Saraswati Sukumar
Journal:  Cancer Biol Ther       Date:  2006-05-06       Impact factor: 4.742

7.  Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling.

Authors:  Nathan T Ihle; Ryan Williams; Sherry Chow; Wade Chew; Margareta I Berggren; Gillian Paine-Murrieta; Daniel J Minion; Robert J Halter; Peter Wipf; Robert Abraham; Lynn Kirkpatrick; Garth Powis
Journal:  Mol Cancer Ther       Date:  2004-07       Impact factor: 6.261

8.  Large-scale allosteric conformational transitions of adenylate kinase appear to involve a population-shift mechanism.

Authors:  Karunesh Arora; Charles L Brooks
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-13       Impact factor: 11.205

9.  Large-scale protein structure modeling of the Saccharomyces cerevisiae genome.

Authors:  R Sánchez; A Sali
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-10       Impact factor: 11.205

10.  A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.

Authors:  Zachary A Knight; Beatriz Gonzalez; Morri E Feldman; Eli R Zunder; David D Goldenberg; Olusegun Williams; Robbie Loewith; David Stokoe; Andras Balla; Balazs Toth; Tamas Balla; William A Weiss; Roger L Williams; Kevan M Shokat
Journal:  Cell       Date:  2006-04-27       Impact factor: 41.582

View more
  9 in total

Review 1.  Somatic mutations in PI3Kalpha: structural basis for enzyme activation and drug design.

Authors:  Sandra B Gabelli; Diana Mandelker; Oleg Schmidt-Kittler; Bert Vogelstein; L Mario Amzel
Journal:  Biochim Biophys Acta       Date:  2009-12-02

2.  Rapid detection of genetic mutations in individual breast cancer patients by next-generation DNA sequencing.

Authors:  Suqin Liu; Hongjiang Wang; Lizhi Zhang; Chuanning Tang; Lindsey Jones; Hua Ye; Liying Ban; Aman Wang; Zhiyuan Liu; Feng Lou; Dandan Zhang; Hong Sun; Haichao Dong; Guangchun Zhang; Zhishou Dong; Baishuai Guo; He Yan; Chaowei Yan; Lu Wang; Ziyi Su; Yangyang Li; Xue F Huang; Si-Yi Chen; Tao Zhou
Journal:  Hum Genomics       Date:  2015-02-08       Impact factor: 4.639

3.  Investigating the structure and dynamics of the PIK3CA wild-type and H1047R oncogenic mutant.

Authors:  Paraskevi Gkeka; Thomas Evangelidis; Maria Pavlaki; Vasiliki Lazani; Savvas Christoforidis; Bogos Agianian; Zoe Cournia
Journal:  PLoS Comput Biol       Date:  2014-10-23       Impact factor: 4.475

4.  Helical and kinase domain mutations of PIK3CA, and their association with hormone receptor expression in breast cancer.

Authors:  Chittibabu Vatte; Ali Mohammed Al Amri; Cyril Cyrus; Shahanas Chathoth; Ahmed Alsayyah; Arafat Ahmad; Mohammed Shakil Akhtar; Nada Fehaid Alrashidi; Nithya Jayaseeli; Hamed Al Wadani; Alhussain Al Zahrani; Amein Kadhem Al Ali
Journal:  Oncol Lett       Date:  2019-07-04       Impact factor: 2.967

5.  The Spectrum, Tendency and Predictive Value of PIK3CA Mutation in Chinese Colorectal Cancer Patients.

Authors:  Xinhui Fu; Hanjie Lin; Xinjuan Fan; Yaxi Zhu; Chao Wang; Zhiting Chen; Xiaoli Tan; Jinglin Huang; Yacheng Cai; Yan Huang
Journal:  Front Oncol       Date:  2021-03-26       Impact factor: 6.244

6.  Therapeutic targeting of ARID1A and PI3K/AKT pathway alterations in cholangiocarcinoma.

Authors:  Supharada Tessiri; Anchalee Techasen; Sarinya Kongpetch; Achira Namjan; Watcharin Loilome; Waraporn Chan-On; Raynoo Thanan; Apinya Jusakul
Journal:  PeerJ       Date:  2022-01-13       Impact factor: 2.984

7.  Bi-directional SIFT predicts a subset of activating mutations.

Authors:  William Lee; Yan Zhang; Kiran Mukhyala; Robert A Lazarus; Zemin Zhang
Journal:  PLoS One       Date:  2009-12-14       Impact factor: 3.240

8.  Utilizing protein structure to identify non-random somatic mutations.

Authors:  Gregory A Ryslik; Yuwei Cheng; Kei-Hoi Cheung; Yorgo Modis; Hongyu Zhao
Journal:  BMC Bioinformatics       Date:  2013-06-13       Impact factor: 3.169

9.  A graph theoretic approach to utilizing protein structure to identify non-random somatic mutations.

Authors:  Gregory A Ryslik; Yuwei Cheng; Kei-Hoi Cheung; Yorgo Modis; Hongyu Zhao
Journal:  BMC Bioinformatics       Date:  2014-03-26       Impact factor: 3.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.